Company news
Satellos Bioscience Inc news in 2022
Satellos Bioscience Inc's news releases, calls and decks from 2022, newest first.
Satellos Bioscience Announces Q3 2022 Financial Results and Operational Highlights
November 23, 2022
Satellos Bioscience Announces Advancement of Compounds to Next Stage of Development
November 3, 2022
Satellos Bioscience Inc. to Present Preliminary Preclinical Proof of Concept Data for an Additional Rare Disease at World Muscle Society Meeting
October 11, 2022
Satellos Bioscience Inc. Announces the Grant of Stock Options
October 6, 2022
Satellos Bioscience Inc. Announces Licensing of Formulation Technology and Expanded Collaboration with NW PharmaTech Ltd.
October 6, 2022
Satellos Bioscience Announces OTCQB Listing in the United States
October 6, 2022
Satellos Bioscience Inc. Announces the Appointment of Philip D. Lambert, Ph.D, as Chief Technology Officer
September 28, 2022
Satellos Bioscience Inc. Announces Closing of Offering of Units
September 13, 2022
Satellos Bioscience Inc. Announces the Filing of Final Short Form Prospectus for Proposed Offering of Units
September 7, 2022
Satellos Bioscience Inc. Announces Pricing of Proposed Offering of Units
August 30, 2022
Satellos Bioscience Inc. Announces the Filing of an Amended and Restated Preliminary Prospectus for Proposed Offering of Units
August 29, 2022
Satellos Bioscience Reports Q2 2022 Financials and Operating Results
August 29, 2022
Satellos Bioscience Co-Founder and Chief Scientific Officer Dr. Michael Rudnicki Awarded Significant Grant from the Canadian Institutes of Health Research
July 25, 2022
Satellos Bioscience Co-Founder and Chief Scientific Officer Dr. Michael Rudnicki Published in Nature Communications
July 13, 2022
Satellos Bioscience Inc. Announces Proposed Offering of Units
July 11, 2022
Satellos Bioscience Announces In-Licensing of New Patent Application
June 29, 2022
Satellos Bioscience Co-Founder and Chief Scientific Officer Dr. Michael Rudnicki Officially Recognized as a Fellow of the Royal Society
June 22, 2022
Satellos Bioscience Co-Founder and Chief Scientific Officer Awarded Prestigious Defeat Duchenne Canada 2022 Grant
June 17, 2022
Satellos Bioscience Inc. to Present at Bio International Convention 2022
June 14, 2022
Satellos Bioscience to Present at the LD Micro Invitational
June 1, 2022
Satellos Bioscience Inc. Announces First Quarter Financial Results and Operational Highlights
May 31, 2022
Satellos Bioscience Announces 2021 Year End Financial Results and Operational Highlights
April 29, 2022
Satellos Bioscience Inc. Invited to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference
April 26, 2022
Satellos Bioscience Inc. to Present Game Changing Science at Upcoming European Molecular Biology Organization Workshop
April 21, 2022
Satellos Bioscience Inc.'s CSO to Present Game Changing Science During March 30th Drug Discovery News Webinar
March 29, 2022
Satellos Bioscience Provides Update on Novel Regenerative Drug Candidates
March 15, 2022
Satellos Bioscience Provides Update on Joint Development Initiative with NW PharmaTech Limited
March 11, 2022
Satellos Bioscience Inc. to Present Game Changing Science at Insights in Research Investor Summit and MDA Clinical & Scientific Conference 2022
March 10, 2022
Satellos Bioscience to Participate at BIO CEO & Investor Conference 2022
February 10, 2022
Satellos Bioscience Inc. Announces CEO Letter to Shareholders
January 24, 2022
Satellos Bioscience to Participate at Biotech Showcase(TM) Virtual 2022
January 6, 2022
Decks in 2022
- Investor Presentation (February 2022)
Investor deck · 21 slides · Feb 22, 2022